Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
Want to see JP:4570 full AI Analyst Report?
4570 Stock Chart & Stats
¥1404.00
¥18.00(3.96%)
At close: 4:00 PM EST
¥1404.00
¥18.00(3.96%)
Day’s Range― - ―
52-Week Range¥464.00 - ¥3,820.00
Previous CloseN/A
Volume75.00K
Average Volume (3M)23.51K
Market Cap
¥11.43B
Enterprise Value¥10.72B
Total Cash (Recent Filing)¥903.75M
Total Debt (Recent Filing)¥196.94M
Price to Earnings (P/E)41.4
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.95
Price to Sales (P/S)4.61
P/FCF Ratio36.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilitySustained gross margin of ~65% plus a 25.7% net margin reflect durable product-level pricing power and efficient cost structure. This margin profile supports repeatable profitability, funds R&D and product validation, and provides a buffer versus competitive pricing pressure over the medium term.
Conservative Balance SheetVery low leverage and a high equity ratio indicate strong capitalization and financial flexibility. This reduces refinancing and solvency risk, enabling the company to fund capex, absorb shocks, or pursue strategic investments without jeopardizing operations over the next 2–6 months and beyond.
Improving Cash Generation And Recurring DemandImproved operating cash flow and a 0.74 cash conversion ratio signal stronger cash generation capability. Coupled with consumable reagent demand (repeat purchases), this creates predictable cash inflows to fund working capital, R&D, and product rollouts, supporting sustainable operations.
Bears Say
Limited Scale / Small HeadcountA small workforce constrains commercial reach, R&D throughput, and manufacturing scale relative to larger peers. This can limit simultaneous product launches, slow geographic expansion, and increase reliance on key individuals, making durable growth execution more challenging over the medium term.
Lack Of Revenue Segmentation TransparencyAbsence of disclosed product- or customer-level revenue breakdown raises uncertainty about concentration risk. Without segmentation, it's harder to assess dependency on a few products or customers, increasing the risk that an adverse shift could materially affect revenues and planning.
Low Visibility On Strategy And InitiativesNo forward guidance and no recent notable corporate events reduce clarity on growth initiatives, capital allocation, and partnerships. This lack of visibility impairs assessment of management's strategic roadmap and the durability of future revenue or margin improvements.
4570 FAQ
What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?
Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.
What is Immuno-Biological Laboratories Co., Ltd.’s market cap?
Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥11.43B.
When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Immuno-Biological Laboratories Co., Ltd. overvalued?
According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued.
Does Immuno-Biological Laboratories Co., Ltd. pay dividends?
Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥6 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here
What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?
Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.
What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4570
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.
Technical Analysis
StemRIM Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―